Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1369 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma Signature Genes and CXCL10 As New Biomarkers in Early Stage of Rheumatoid Arthritis
Kijun Lee¹, Jennifer Lee², Hong-Ki Min¹, Hae-Rim Kim³, Sang-Heon Lee⁴, Sung-Hwan Park⁵, Ji Hyeon Ju⁶ and Hoyoun Kim¹, ¹The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Konkuk University Medical Center, Seoul, Korea, Republic of (South), ⁴Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine,, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 2426 • 2017 ACR/ARHP Annual Meeting
Altered Frequencies of Circulating Follicullar T Helper Cell Counterparts and Their Subsets but Not of Peripheral Helper T Cells, Are Associated with Increased Circulating Plasmablasts in Seropositive Early RA Patients
Paula Fortea-Gordo¹, Lorena Valdeolivas-De Opazo¹, Laura Nuño², Alejandro Villalba¹, Paloma Sanchez-Mateos³, Amaya Puig-Kröger⁴, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁴Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: Follicular T helper (Tfh) cells are typically located in lymphoid organs where they promote B cell differentiation and function. Circulating CD4 T cells expressing…
Abstract Number: 1386 • 2017 ACR/ARHP Annual Meeting
Tenosynovitis in the Forefoot at Disease Presentation Is Specific for RA: Results from a Cross-Sectional MRI Study in Early Arthritis
Yousra J. Dakkak¹, Debbie M. Boeters², Annette H.M. van der Helm-van Mil² and M. Reijnierse³, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The foot is a preferential location for rheumatoid arthritis (RA)-manifestation, but physical examination of the metatarsophalangeal (MTP) joints is difficult. Magnetic Resonance Imaging (MRI)…
Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Arthur Kavanaugh¹, Ronald F van Vollenhoven², Prashanth Sunkureddi³, Ying Zhang⁴, Jessica L. Suboticki⁵ and Josef S. Smolen⁶, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Mettawa, IL, ⁶Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…
Abstract Number: 1393 • 2017 ACR/ARHP Annual Meeting
Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis
Cheryl Barnabe¹, Orit Schieir², Glen Hazlewood¹, Susan J. Bartlett³, Carol A Hitchon⁴, Janet E. Pope⁵, Gilles Boire⁶, Edward C. Keystone⁷, Diane Tin⁸, B Haraoui⁹, Vivian P. Bykerk¹⁰ and Carter Thorne¹¹, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada
Background/Purpose: Outcomes in ERA are largely thought to reflect individual prognostic factors and treatment strategy employed. We hypothesize that an additional factor may be the…
Abstract Number: 2939 • 2017 ACR/ARHP Annual Meeting
Clinical Correlate of Synovial Proliferation in Early Rheumatoid Arthritis
Fan XIAO¹, JIANG YUE², Queenie Mak³, Lai-Shan Tam⁴ and James F Griffith⁵, ¹Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, HONG KONG, Hong Kong, ³Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, HONGKONG, Hong Kong
Clinical Correlate of Synovial Proliferation in Early Rheumatoid Arthritis Background/Purpose: To determine whether semi-quantitative, quantitative assessment of synovitis severity or synovial perfusion data correlates best…
Abstract Number: 508 • 2016 ACR/ARHP Annual Meeting
Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms
Leonie E Burgers¹, Hanna W van Steenbergen¹, Lukas Mangnus², Tom WJ Huizinga¹ and Annette HM van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibody (ACPA)-positive and ACPA-negative rheumatoid arthritis (RA) have different genetic risk factors and underlying biological mechanisms. Therefore, we hypothesized that patients’ characteristics…
Abstract Number: 1515 • 2016 ACR/ARHP Annual Meeting
Could Increase Levels of Dickkopf-1 Protein be Considered As a Potential Biomarker for Bone Resorption in Joint and Periodontal Disease in Patients with Early Rheumatoid Arthritis?
ANA MARIA HEREDIA PALAU¹, SEBASTIAN GIRALDO QUINTERO^2,3, JULIETTE DE AVILA¹, LORENA CHILA MORENO⁴, GLORIA LAFAURIE⁵, CONSTANZA RODRIGUEZ⁴, WILSON BAUTISTA-MOLANO^5,6, PHILLIPE CHALEM CHOUEKA⁷, JUAN MANUEL BELLO GUALTEROS^3,8, RAFAEL VALLE-OÑATE^3,8 and CONSUELO ROMERO-SÁNCHEZ^4,9,10, ¹Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogota, Colombia, ²Rheumatology and Immunology Department,Hospital Militar Central, Bogota, Colombia, ³School of Medicine, Universidad Militar Nueva Granada, Bogota, Colombia, ⁴Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, BOGOTA, Colombia, ⁵Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁶School of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia, ⁷Fundación Instituto de Reumatología Fernando Chalem, Bogotá, Colombia, ⁸Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia, ⁹Rheumatology and Immunology Department,Hospital Militar Central, BOGOTA, Colombia, ¹⁰School of Medicine, Universidad Militar Nueva Granada, BOGOTA, Colombia
Background/Purpose: Periodontitis and rheumatoid arthritis (RA) are chronic destructive inflammatory diseases with significant worldwide prevalence. They are characterized by inflammatory lesions adjacent to bone destruction…
Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Liam O'Neil¹, Xiaobo Meng², Irene Smolik³, Carol Hitchon² and Hani El-Gabalawy⁴, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…
Abstract Number: 567 • 2016 ACR/ARHP Annual Meeting
Understanding Contextual Factors That Influence Decisions Related to Health and Work Among People with Recently Diagnosed Rheumatoid Arthritis
Graham Macdonald¹, Catherine Backman², Anne F. Townsend³ and Linda Li⁴, ¹Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ²Occup Science & OccupTherapy, University of British Columbia, Vancouver, BC, Canada, ³Qualitative Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Department of Physical Therapy, The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA), early diagnosis and treatment are essential to better outcomes. Many people defer seeking help or treatment for reasons that are…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 3226 • 2016 ACR/ARHP Annual Meeting
Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Tatsuya Atsumi², Kazuhiko Yamamoto³, Tsutomu Takeuchi⁴, Hisashi Yamanaka⁵, Naoki Ishiguro⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Pauline Ralston¹¹, Désirée van der Heijde¹², Nobuyuki Miyasaka^13,14 and Takao Koike¹⁵, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Tokyo Women's Medical University, Tokyo, Japan, ⁶Nagoya University, Nagoya, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Hays Pharma, London, United Kingdom, ¹²Leiden University Medical Center, Leiden, Netherlands, ¹³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Sapporo Medical Center NTT EC, Sapporo, Japan
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) treatment in combination with dose-optimized MTX in Japanese MTX-naïve early RA patients (pts) with poor prognostic…
Abstract Number: 593 • 2016 ACR/ARHP Annual Meeting
Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Josef S. Smolen¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Su Chen³, Jessica L. Suboticki³ and Arthur Kavanaugh⁴, ¹Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria, ²Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA
Background/Purpose: In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who…
Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA Study Group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…
Abstract Number: 594 • 2016 ACR/ARHP Annual Meeting
Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Clifton Bingham III¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Brenda VanLunen⁸, Oana Purcaru⁹ and Vivian P. Bykerk¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²University of Leeds, Leeds, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of physical function, work disability, and decreased quality of life. Early treatment with certolizumab pegol (CZP) in…

« Previous Page
1
…
5
6
7
8
9
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.